Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids

Head and Neck

Volumn 32, Issue 9, 2010, Pages 1209-1216

  Lee, Walter T ^a   Tan, Chunrui ^a   Koski, Gary ^b   Shu, Suyu ^c   Cohen, Peter ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c EARLE A CHILES RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

dendritic cell; fusion hybrid; immunotherapy; squamous cell carcinoma; vaccine

Indexed keywords

H2 ANTIGEN; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C3H MOUSE; CANCER IMMUNOTHERAPY; CELL FUSION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HYBRID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRID CELLS; IMMUNOTHERAPY; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HOMOLOGOUS;

EID: 78349296408     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21323     Document Type: Article

References (19)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
2. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064-1071.
3. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature 1998; 293: 245-252.
4. Dubsky P, Hayden H, Sachet M, et al. Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. Cancer Immunol Immunother 2008; 57: 859-870.
5. Ren J, Jia J, Zhang H, et al. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Sci 2008; 99: 1420-1426.
6. Chan T, Sami A, El-Gayed A, Guo X, Xiang J,. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 2006; 13: 1391-1402.
7. Kjaergaard J, Shimizu K, Shu S,. Electrofusion of syngeneic dendritic cells and tumor generated potent therapeutic vaccine. Cell Immunol 2003; 225: 65-74.
8. Kuriyama H, Shimizu K, Lee W, et al. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol 2004; 116: 169-178.
9. Hayashi T, Tanaka H, Tanaka J, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002; 104: 14-20.
10. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchy KD, Regezi JA,. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981; 107: 703-710.
11. Novellino L, Chiara Castelli C, Parmiani G,. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207.
12. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006; 55: 451-458.
13. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunol 2008; 31: 101-112.
14. Tsioulias GJ, Gupta RK, Tisman G, et al. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 2001; 8: 198-203.
15. Lee WT, Shimizu K, Kuriyama H, Tanaka H, Kjaergaard J, Shu S,. Tumor-dendritic cell fusion as basis for cancer vaccine. Otolaryngol Head Neck Surg 2005; 132: 755-764.
16. Morton DL,. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Dev Biol 2004; 116: 209-217.
17. Urba WJ, Nemunaitis J, Marshall F, et al. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 2008; 180: 2011-2017.
18. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007; 25: 2078-2085.
19. Mathers AR,., Larregina AT,. Professional antigen-presenting cells of the skin. Immunol Res 2006; 36: 127-136.